Clinical Trials Logo

Clinical Trial Summary

This is a Phase I, open-label study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of AZD4635 in Japanese patients with advanced solid malignancies. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in Cohort1 and 6 evaluable patients will be enrolled in Cohort2.


Clinical Trial Description

Objectives: Primary objective: Investigate the safety and tolerability of AZD4635 monotherapy in Japanese patients Secondary objective: Characterize the single-dose and multiple-dose plasma pharmacokinetic (PK) parameters of AZD4635 monotherapy Determine the preliminary anti-tumor activity of AZD4645 monotherapy Overall design: This is a phase I, open-label study of AZD4635 in Japanese patients with advanced solid malignancies. The study consists of 2 cohorts, Cohort 1 and Cohort 2. At least 3 or up to 6 evaluable Japanese subjects with advanced solid malignancies will be enrolled in Cohort 1 and 6 evaluable patients will be required for Cohort 2 to confirm the tolerability. The total number of evaluable subjects in each cohort will depend upon available data in each cohort and decision of Safety Review Committee(SRC). Study Period: The study is expected to start in June 2019 and end in June 2020. Number of Subjects: 9 to 12 evaluable subjects will be enrolled in this study to confirm the tolerability. Treatments and treatment duration: Subjects will receive AZD4635 once daily (QD). A single dose of AZD4635 will be taken on Cycle 0 Day1 and the subsequent dose of AZD4635 will be taken from Cycle 1 Day 1 until discontinuation criterion is met. A cycle of study treatment will be defined as 21 days of continuous dosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03980821
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date July 4, 2019
Completion date September 7, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02080078 - A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Phase 1
Completed NCT00981721 - A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00351325 - A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies Phase 1
Completed NCT00295243 - Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies Phase 1
Recruiting NCT02347228 - Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00979134 - Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours Phase 1
Completed NCT00997945 - 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT05573724 - Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies Phase 1
Completed NCT03736473 - A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients Phase 1
Completed NCT02260661 - Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours Phase 1
Completed NCT01213160 - Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient Phase 1
Terminated NCT01219543 - A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. Phase 1
Completed NCT00572364 - Open Label, Dose Escalation Phase I Study of AZD2281 Phase 1
Completed NCT03363893 - Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Phase 1/Phase 2
Active, not recruiting NCT04606381 - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies Phase 1
Recruiting NCT05315167 - A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00879905 - A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT00473616 - Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan Phase 1
Recruiting NCT05159700 - A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01813474 - Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies Phase 1